BioArctic partners with Eisai on Alzheimer’s treatment
上市批准
Preview
来源: Pharmaceutical Technology
The research will assess potential next-generation disease-modifying treatment for Alzheimer’s disease. Credit: Dragana Gordic via Shutterstock.
Swedish research-based biopharma company BioArctic has signed an agreement with Eisai for a research evaluation focusing on BAN2802, a novel Alzheimer’s disease (AD) treatment candidate.
The BrainTransporter technology is intended to actively transport antibodies across the blood-brain barrier to enhance the treatment efficacy.
Eisai, at the end of the collaboration, will assess the data generated. It can then decide to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease.
BioArctic and Eisai’s partnership dates back to 2005, for the development and commercialisation of drugs for Alzheimer’s disease treatment.
See Also:
BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using AVPAL variant
Preview
来源: Pharmaceutical Technology
Purdue Pharma gets grant for treatment of T-cell prolymphocytic leukemia using tinostamustine
Preview
来源: Pharmaceutical Technology
Their collaboration has already resulted in the development of Leqembi (lecanemab), a drug that slows the progression of early Alzheimer’s disease.
The new partnership aims to further this success in the field of Alzheimer’s disease.
BioArctic CEO Gunilla Osswald said: “I am very happy that our Brain Transporter technology has continued to progress so well and that we have now entered into this first agreement utilising this platform. I believe that this technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders.
“Together, we have been able to deliver lecanemab, the first fully approved disease-modifying treatment in Alzheimer’s disease in the US, Japan and China, and we look forward to continuing our fruitful collaboration and lead the development of the next generation of drugs to help patients with this devastating disease.”
The research evaluation programme will be a joint financial effort. It will assess potential next-generation disease-modifying treatments for AD.
BioArctic said its BrainTransporter technology facilitates the active transport of biologics across the blood-brain barrier into the brain, potentially leading to more rapid and potent treatment outcomes.
Earlier this year, BioArctic and Eisai obtained approval for the amyloid beta-directed antibody Leqembi in China to treat mild cognitive impairment associated with Alzheimer’s disease and mild AD dementia.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。